Intuitive Surgical, Inc.

(NASDAQ Global Select)
Back to all articles
Somewhat Bearish -25

Intuitive Surgical: A Monopoly Business, a Decelerating Growth Story ...

Analyst downgrade Company update Earnings report AI-generated analysis

📈 ISRG delivered Q2 revenue of $2.89 billion and adjusted EPS of $2.80, beating consensus estimates of $2.82 billion and $2.51 respectively.

📉 Shares dropped 11% on the news as management guided for decelerating procedure growth and announced price cuts for instruments starting in H1 2027.

💰 Approximately 60% of ISRG's revenue comes from high-margin instruments and accessories, which are directly threatened by the planned pricing strategy.

📊 The company trades at roughly 47x trailing earnings, significantly higher than peers like Stryker (28.5x) and Boston Scientific (16.6x).

🔬 Worldwide da Vinci procedures grew 16% year over year in the June quarter, though US growth is decelerating due to affordability pressures.

🛠️ The da Vinci 5 system ramp continues with 246 of 468 systems placed in the quarter being the newer generation model.

🌍 International placement and new FDA clearances for mitral-valve repair are expanding the addressable market for the company.

📉 Analyst consensus is a 'Moderate Buy' but recent actions include downgrades to 'Hold' due to concerns over stretched valuations and margin compression.

🎯 The recurring revenue model relies on procedure volume, which could be negatively impacted if price cuts fail to stimulate demand sufficiently.

🔮 Investors are awaiting the October 20 fiscal Q3 report for signs that procedure growth has stabilized or that volume offsets price reductions.

Bullish Signals
  • ISRG beat Q2 revenue and EPS estimates, demonstrating strong execution despite macro headwinds.
  • Worldwide da Vinci procedures grew 16% year over year in the June quarter, indicating robust global demand.
  • The company is ramping the newer da Vinci 5 system, with 246 of 468 systems placed in the quarter being the latest generation.
  • New FDA clearances for mitral-valve repair open a significant opportunity estimated near 160,000 procedures annually.
  • International placement continues to expand, diversifying revenue streams beyond the US market.
  • The recurring revenue model from instruments and accessories provides stability and scales with surgeon utilization.
Risk Factors
  • Management signaled slowing growth and plans price cuts on key instruments starting in H1 2027, threatening the high-margin recurring revenue engine.
  • US procedure growth is decelerating due to affordability pressures at both provider and patient levels.
  • The stock trades at roughly 47x trailing earnings, double the average of large-cap device peers, creating valuation risk if growth slows.
  • Analysts are split with some downgrading to 'Hold' citing that the premium valuation requires exceptional performance to justify.
  • Price cuts on instruments directly threaten the 67% gross margins and 31% operating margins that drive the company's profitability.
Full Analysis
Intuitive Surgical (ISRG) reported second-quarter revenue of $2.89 billion and adjusted EPS of $2.80, both beating Wall Street estimates. Despite the financial beat, shares fell 11% as management signaled a deceleration in growth trajectory and announced plans to cut prices on key instrument lines starting in the first half of 2027. The company's high-margin recurring revenue model, which accounts for roughly 60% of its $10.1 billion fiscal 2025 revenue, faces direct pressure from these planned price reductions. While worldwide da Vinci procedures grew 16% year over year in the quarter, guidance for full-year procedure growth was lowered to approximately 14.5%, reflecting concerns about slowing US adoption and affordability pressures at both provider and patient levels. Valuation scrutiny remains a primary concern as ISRG trades at roughly 47x trailing earnings, double the average of large-cap device peers like Stryker and Boston Scientific. Analyst consensus is split between 'Moderate Buy' ratings and caution over stretched multiples, with some firms downgrading to 'Hold' citing that the premium valuation requires exceptional performance to justify the slowing growth rate and margin compression risks. Looking ahead, the stock's recovery depends on either a significant multiple contraction or evidence that volume gains offset price cuts. The da Vinci 5 system ramp and international expansion provide stability, but investors are watching closely for stabilization in procedure growth rates in the upcoming October fiscal Q3 report to validate the company's long-term franchise value.